Ultimately, survival analyses — assessing overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI) — firmly established SYT4 as a potential oncogene and prognostic predictor in GC (Fig. 1G and Supplementary Figure S1). This evidence concerns the gene SYT4 and gastric cancer.